Transgenic Animal Model Market Poised to Reach $6.79 Billion by 2035, Driven by CRISPR and Precision Medicine
Key Insights
The global transgenic animal model market is projected to grow from $2.79 billion in 2025 to $6.79 billion by 2035 at a CAGR of 9.2%, fueled by rising pharmaceutical R&D and genetic engineering advances.
CRISPR/Cas9 (search) technology dominates the market with a 44.96% share in 2024, enabling rapid, precise creation of disease models for oncology, neurology, and rare genetic disorders.
Rodents, particularly mice, account for 74.96% of the animal type segment, while pharmaceutical and biotechnology companies represent 57.38% of end-user demand.
The global transgenic animal model market is on a trajectory of robust expansion, with projections indicating growth from an estimated $2.79 billion in 2025 to $6.79 billion by 2035, reflecting a compound annual growth rate (CAGR) of 9.2%, according to a comprehensive market analysis by ResearchAndMarkets.com. This growth is underpinned by accelerating pharmaceutical research and development activities, the rapid adoption of CRISPR/Cas9 (search) gene-editing technology, and the expanding role of personalized medicine in drug discovery.
Within Europe, the market is forecast to climb from $906.5 million in 2025 to $2.23 billion by 2035, achieving a CAGR of 9.44%. Germany, the U.K., and France are identified as the leading contributors, leveraging strong research infrastructure and supportive regulatory frameworks to drive innovation in genetic engineering and biomedical research.
CRISPR/Cas9 (search) Dominates the Technology Landscape
CRISPR/Cas9 (search) has emerged as the dominant technology in the transgenic animal model market, capturing a 44.96% share in 2024. The gene-editing platform has transformed the field by enabling precise gene knock-ins, knockouts, and edits at specific genomic locations with greater speed, accuracy, and cost-effectiveness compared to traditional methods such as microinjections and embryonic stem cell injections.
"CRISPR/Cas9 (search) has revolutionized the transgenic animal model market due to its precision, efficiency, and versatility in genetic modifications," the report states, noting that the technology has significantly accelerated the creation of animal models used in disease research, drug discovery, and personalized medicine. Applications span gene therapy, cancer research, and neurodegenerative disease modeling, with companies and research institutions increasingly relying on CRISPR to generate complex animal models for therapeutic development.
Rodents Remain the Model Organism of Choice
By animal type, rodents—particularly mice—dominate the market with a 74.96% share in 2024. Over 95% of transgenic animals used in biomedical research are rodents, a dominance attributed to the extensive characterization of the mouse genome and its genetic similarity to humans. Genetically modified mice are extensively employed to model Alzheimer's disease (search), enabling the study of amyloid plaques and the testing of therapies such as Aduhelm. In cancer research, p53 knockout mice are used to replicate human tumor growth and evaluate treatments including CAR-T cell therapy.
The mouse's short reproduction cycle, suitability for physiologic and behavioral testing, and adaptability to controlled laboratory environments further reinforce its position as the preferred model organism for large-scale preclinical studies.
Drug Discovery and Development Leads Application Segments
The drug discovery and development segment commanded a 54.19% share of the global market in 2024, reflecting its role as the primary user of transgenic models across the full preclinical workflow—from target validation and mechanism-of-action studies to efficacy screening and early safety assessment. Pharmaceutical and biotechnology companies are allocating higher budgets to transgenic and humanized models, particularly for oncology, metabolic disorders, neurodegenerative diseases, and advanced modalities including immuno-oncology and gene and cell therapies.
Pharmaceutical and biotechnology companies themselves represent the largest end-user segment, holding a 57.38% market share in 2024. These organizations rely on genetically engineered animals to de-risk development by validating drug targets, interrogating disease pathways, generating efficacy and safety data, and refining dose regimens prior to first-in-human studies.
Personalized Medicine and Industry Momentum
The growing emphasis on personalized medicine is significantly increasing demand for transgenic animal models, especially humanized mice engineered to express human genes or mutations. These models are critical for testing gene therapies, immunotherapies, and patient-specific drug regimens. Humanized mouse models are used in HIV research to evaluate antiretroviral drugs, while patient-derived xenograft (PDX) models help assess how personalized therapies perform against a patient's unique genetic makeup.
Recent industry developments underscore the market's momentum. In August 2025, Taconic Biosciences (search) collaborated with Cyagen Biosciences to offer researchers streamlined access to a library of over 16,000 genetically engineered mouse models. In July 2025, Biocytogen Pharmaceuticals (search) announced a major upgrade to its preclinical business division, broadening its range of genetically engineered animal models including target-humanized, immune-humanized, transgenic, and immunodeficient mice. Earlier, in June 2024, Biocytogen received a U.S. patent for its RenLite platform, which enables the creation of fully human antibodies with a common light chain, simplifying the development of bispecific antibodies and antibody-drug conjugates (ADCs).
Challenges and Regional Dynamics
Despite strong growth prospects, the market faces notable challenges. High maintenance costs represent a significant barrier, with maintaining inbred C57BL/6 mice costing upwards of $3,500 for animal purchase alone, excluding additional expenses for cage upkeep, veterinary care, and specialized procedures. Ethical concerns regarding animal testing and genetic modification, along with stringent regulatory requirements across European countries, further constrain market expansion, particularly for smaller biotech firms and academic laboratories.
North America maintains a dominant position in the global market, supported by the largest concentration of biopharma R&D activity, a robust regulatory environment, and early adoption of precision medicine and cell and gene therapies. Regulatory agencies including the FDA and Health Canada actively engage with emerging therapeutic modalities, spurring demand for predictive animal models that meet stringent evidentiary standards.
Key players profiled in the market include Charles River Laboratories International, Inc., Creative Biolabs, Alloy Therapeutics (search), Inc., Inotiv, HuidaGene, genOway, Ingenious Targeting Laboratory, OmniAb Inc., Taconic Biosciences (search), Biocytogen Pharmaceuticals (search), Merck Group (search), and Janvier Group.